Stocktoria
MADRIGAL PHARMACEUTICALS, INC. MDGL
MADRIGAL PHARMACEUTICALS, INC. (MDGL) earns a Piotroski F-score of 3/9 (weak financial health), with an Altman Z″ in the distress zone. It does not currently pay a dividend. FY2025 revenue was $958.4M at a -30.1% net margin.
Quality score trend · recomputed for each fiscal year
Each year's score is computed from that year's filing — a rising Piotroski F or Altman Z″ means improving financial health, a fall is worth a look.
Analyst price target
Recent analyst actions
| Date | Firm | Rating |
|---|---|---|
| 2026-08-04 | Wolfe Research | Outperform (up) |
| 2026-08-03 | Barclays | Overweight (main) |
| 2026-07-29 | Canaccord Genuity | Buy (main) |
| 2026-07-27 | Wells Fargo | Overweight (init) |
| 2026-06-11 | B of A Securities | Neutral (main) |
| 2026-05-13 | Truist Securities | Buy (main) |
Wall Street analyst consensus — a sentiment gauge, not our scoring.
Forward estimates · earnings calendar →
Consensus analyst estimates and scheduled dates — forward-looking, may change.
Smart money · insiders, last 12 months
Open-market insider purchases minus sells (SEC Form 4) — real buying with their own money is a bullish “smart money” signal; grants and option exercises are excluded.
How it ranks in Manufacturing · percentile among 1957 companies
Percentile vs other Manufacturing companies we cover — e.g. “stronger than 90%” means only 10% score higher on that measure.
Piotroski F breakdown · 3/9 tests passed
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″ components · distress zone
| Component | Value |
|---|---|
| Working capital / assets | 0.743 |
| Retained earnings / assets | -1.66 |
| EBIT / assets | -0.238 |
| Equity / liabilities | 0.917 |
Sector peers · similar-size Manufacturing companies compare side by side →
| Ticker | Company | Piotroski F | Altman Z″ | P / E | Revenue growth |
|---|---|---|---|---|---|
| MDGL | MADRIGAL PHARMACEUTICALS, INC. | 3/9 | -1.18 | — | +432.1% |
| IONS | IONIS PHARMACEUTICALS INC | 3/9 | 1.12 | — | +33.8% |
| ANIP | ANI PHARMACEUTICALS INC | 6/9 | 3.26 | 24.5 | +43.8% |
| HRMY | Harmony Biosciences Holdings, Inc. | 5/9 | 7.17 | 12.9 | +21.5% |
| ACAD | ACADIA PHARMACEUTICALS INC | 4/9 | 3.79 | 11.1 | +11.9% |
| ARWR | ARROWHEAD PHARMACEUTICALS, INC. | 4/9 | 0.82 | — | — |
| PBH | Prestige Consumer Healthcare Inc. | 5/9 | 4.04 | 12.3 | -4.3% |
About MADRIGAL PHARMACEUTICALS, INC.
Madrigal Pharmaceuticals, Inc., a biopharmaceutical company, focuses on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH) in the United States. It offers Rezdiffra, a liver-directed thyroid hormone receptor beta agonist for treating MASH. The company was founded in 2016 and is headquartered in West Conshohocken, Pennsylvania.
FAQ
Is MDGL financially healthy?
MADRIGAL PHARMACEUTICALS, INC.'s Piotroski F-score is 3/9 (8–9 is excellent, 0–3 weak), and its Altman Z″ distress score is in the distress zone.
Does MDGL pay a dividend?
No, MADRIGAL PHARMACEUTICALS, INC. does not currently pay a dividend.
How profitable is MDGL?
In FY2025, MADRIGAL PHARMACEUTICALS, INC. had a net margin of -30.1% and a return on equity of -47.8%.
What is the analyst price target for MDGL?
The average Wall-Street price target for MADRIGAL PHARMACEUTICALS, INC. is $678.06, about 26.5% above the recent price, from 16 analysts (consensus: strong buy).
Is MDGL a good stock to buy?
Stocktoria doesn't give buy or sell advice, but here is the data on MADRIGAL PHARMACEUTICALS, INC.: a Piotroski F-score of 3/9, an Altman Z″ in the distress zone. Weigh these quality and valuation signals against your own goals.
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.